Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Frank Buttgereit, J. W. J. Bijlsma et al.|Annals of the Rheumatic Diseases|2016Cited by 331
Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meetingJochen Schmitt, Hywel C Williams, Christian Apfelbacher et al.|Allergy|2012Cited by 189
Radiologic features in juvenile idiopathic arthritis: A first step in the development of a standardized assessment methodMarion A. J. van Rossum, Aeilko H. Zwinderman, Maarten Boers et al.|Arthritis & Rheumatism|2003Cited by 89
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trialsThomas Buttgereit, Frank Buttgereit, Andriko Palmowski et al.|Age and Ageing|2021Cited by 48
Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain setJoanna Tieu, Catherine Hill, Jonathan TL. Cheah et al.|Seminars in Arthritis and Rheumatism|2021Cited by 12